SLAM
PVLA

Swiss Life Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Swiss Life Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-471
Closed -$260K – 1751
2026
Q1 		$260K Buy
+471
New +$49.1K ﹤0.01% 1210

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Swiss Life Asset Management's PVLA Position: Q2 2026 in Review

Swiss Life Asset Management sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 471 shares — an estimated $260K sold.

Swiss Life Asset Management first reported a position in PVLA in Q1 2026 and held it in 1 quarter. The position peaked at $260K in Q1 2026. 110 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Swiss Life Asset Management reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Swiss Life Asset Management sold 471 Palvella Therapeutics shares in Q2 2026, an estimated $260K.
  • Swiss Life Asset Management first reported a position in Palvella Therapeutics in Q1 2026 and held it in 1 quarter.
  • Swiss Life Asset Management's Palvella Therapeutics position peaked at $260K in Q1 2026.
  • 110 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.